Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01365
Abstract: PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall… read more here.
Keywords: oncology; ide cel; idecabtagene vicleucel; relapsed refractory ... See more keywords
Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.3.3381592
Abstract: The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with autologous stem cell transplantation, has… read more here.
Keywords: idecabtagene vicleucel; review; advances idecabtagene; vicleucel relapsed ... See more keywords
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2022-0045
Abstract: Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual… read more here.
Keywords: care triple; versus conventional; idecabtagene vicleucel; triple class ... See more keywords
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Future oncology"
DOI: 10.2217/fon-2021-1090
Abstract: Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have… read more here.
Keywords: vicleucel ide; idecabtagene vicleucel; car cell; ide cel ... See more keywords